FrancophonIA/ELRC3.0 huggingface dataset:
English: Eg Labo - Laboratoires Eurogenerics "Le Quintet" - bâtiment A 12, rue Danjou
Estonian: Prantsusmaa Eg Labo - Laboratoires Eurogenerics "Le Quintet" - bâtiment A 12, rue Danjou
English: Les Trois Moulins Parc de Sophia Antipolis 06600 Antibes France
Estonian: Parc de Sophia Antipolis 06600 Antibes
English: Arrow Generiques 26, avenue Tony Garnier 69007 Lyon
Estonian: Prantsusmaa Arrow Generiques 26, avenue Tony Garnier 69007 Lyon
English: Sanofi Aventis France 1-13, boulevard Romain Rolland 75014 Paris
Estonian: Prantsusmaa Sanofi Aventis France 1-13, boulevard Romain Rolland 75014 Paris
English: Breakable tablet
Estonian: Suus dispergeeruv tablett
English: 160 00 Praha 6 - Vokovice Czech Republic
Estonian: Evropská 846/176a 160 00 Praha 6 - Vokovice Czech Republic
English: 3, avenue de la Baltique ZI de Courtaboeuf 91140 Villebon Sur Yvette France
Estonian: Prantsusmaa Alter 3, avenue de la Baltique ZI de Courtaboeuf 91140 Villebon Sur Yvette France
English: 110, Esplanade du Général de Gaulle
Estonian: Prantsusmaa Teva Sante 110, Esplanade du Général de Gaulle
English: Laboratoires Pharmy II 26, rue des Gaudines 78100 Saint-Germain-en-Laye France
Estonian: Prantsusmaa Laboratoires Pharmy II 26, rue des Gaudines 78100 Saint-Germain-en-Laye France
English: Laboratoires Genevrier S.A. 280, rue de Goa Z.I.
Estonian: Prantsusmaa Laboratoires Genevrier S.A. 280, rue de Goa
English: Farmaceutici Caber S.P.A. Viale Citta' D'Europa, 681 Rome
Estonian: Viale Citta' D'Europa, 681 Rome
English: 15, boulevard Charles de Gaulle 92700 Colombes France
Estonian: Prantsusmaa Biogaran 15, boulevard Charles de Gaulle 92700 Colombes France
English: 22 quai Gallieni 92150 Suresnes France
Estonian: Prantsusmaa Cristers 22 quai Gallieni 92150 Suresnes France
English: Actavis Group PTC ehf Reykjavikurvegur 76-78 220 Hafnarfjordur Iceland
Estonian: Prantsusmaa Actavis Group PTC ehf Reykjavikurvegur 76-78
English: DAIICHI SANKYO France SAS Immeuble le Corosa 1, rue Eugene et Armand Peugeot 92508 Rueil Malmaison France
Estonian: 1, rue Eugene et Armand Peugeot 92508 Rueil Malmaison
English: Ratiopharm(Germany) Graf Arco Strasse 3 89079 Ulm
Estonian: Prantsusmaa Ratiopharm(Germany) Graf Arco Strasse 3
English: MYOPLEGE 4 mg, gélule
Estonian: MYOPLEGE 4 mg, gélule 4mg
English: Acarpia Servicos Farmaceuticos Lda Rua dos Murcas, 88
Estonian: Rua dos Murcas, 88
English: Orodispersible tablet Oral use
Estonian: Poolitusjoonega tablett Suukaudne
English: TIOCOLCHICOSIDE ZENTIVA 4mg
Estonian: TIOCOLCHICOSIDE ZENTIVA
English: The overall treatment period should not be longer than 20 days.
Estonian: Ravi kogukestus ei tohi ületada 20 päeva.
English: Patients should be monitored after each infusion.
Estonian: Patsiente tuleb pärast iga infusioonikorda jälgida.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Removab to Fresenius Biotech GmbH on 20 April 2009.
Estonian: Euroopa Komisjon andis Removabi müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele Fresenius Biotech GmbH 20. aprillil 2009.
English: It is usually given as four infusions in increasing doses from 10 to 150 micrograms over 11 days.
Estonian: Ravimit manustatakse tavaliselt nelja suureneva infusiooniannusena 10 kuni 150 mikrogrammi kaupa 11 päeva jooksul.
English: Removab must not be given all at once or by any other route.
Estonian: Removabi ei tohi manustada ühekorraga ega ühelgi muul viisil.
English: The Committee recommended that Removab be given marketing authorisation.
Estonian: Komitee soovitas anda Removabile müügiloa.
English: Around 90% of patients treated with Removab have side effects.
Estonian: Ligikaudu 90%-l Removabi-ravi saavatest patsientidest esineb kõrvalnähte.
English: It is used when standard treatment is not available or is no longer feasible.
Estonian: Ravimit kasutatakse juhtudel, kus standardravi ei saa kasutada või ei ole enam teostatav.
English: There must be an interval of at least two days between infusions, but the interval can be increased if the patient has side effects.
Estonian: Infusioonikordade vahele peab jääma vähemalt kaks päeva, kuid kõrvalnähtude korral võib vahet pikendada.
English: Removab is not recommended for use in patients below the age of 18 years because of a lack of information on safety and effectiveness in this age group.
Estonian: Removabi ei soovitata kasutada noorematel kui 18-aastastel patsientidel, sest selle vanuserühma kohta ravimi ohutuse ja efektiivsuse teave puudub.
English: EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) REMOVAB EPAR summary for the public
Estonian: EUROOPA AVALIK HINDAMISARUANNE REMOVAB Kokkuvõte üldsusele
English: Patients who have severe problems with their liver, or moderate or severe kidney problems should only be given Removab treatment after careful consideration of the medicine's benefits and risks.
Estonian: Raskete maksaprobleemide ning mõõdukate või raskete neeruprobleemidega patsientidele võib ravi Removabiga toimuda üksnes pärast ravimi kasulikkuse ja riskide hoolikat kaalumist.
English: T-cells are part of the immune system (the body's natural defences), and are involved in coordinating the death of infected and abnormal cells.
Estonian: T-rakud on osa immuunsüsteemist (organismi loomulikust kaitsesüsteemist) ning osalevad nakatunud ja ebanormaalsete rakkude hävitamise koordineerimises.
English: The most common side effects with Removab (seen in more than 1 patient in 10) are lymphopenia (low level of lymphocytes, a type of white blood cell), abdominal (tummy) pain, nausea (feeling sick), vomiting, diarrhoea, pyrexia (fever), fatigue (tiredness), chills and pain.
Estonian: Removabi kõige sagedamad kõrvalnähud (esinenud enam kui ühel patsiendil kümnest) on lümfopeenia (valgeliblede lümfotsüütide vähesus), kõhuvalu, iiveldus, oksendamine, kõhulahtisus, püreksia (palavik), väsimus, külmavärinad ja valu.
English: Before treatment, it is recommended that patients are given medicines to reduce pain, fever and inflammation.
Estonian: Enne ravi on patsientidele soovitatav anda valuvaigisteid ning palaviku- ja põletikuravimeid.
English: Other information about Removab:
Estonian: Muu teave Removabi kohta
English: Removab can only be used in patients with EpCAM-positive carcinomas.
Estonian: Removabi võib kasutada üksnes EpCAM-positiivset kartsinoomi põdevatel patsientidel.
English: Removab was studied in one main study involving 258 patients with malignant ascites caused by an EpCAM-positive cancer and for which standard therapy was not available or was no longer feasible.
Estonian: Removabi uuriti ühes põhiuuringus, milles osales 258 patsienti, kellel oli EpCAM-positiivsest vähist põhjustatud pahaloomuline astsiit, mille ravimiseks standardravi ei saanud kasutada või ei olnud see enam teostatav.
English: The main measure of effectiveness was how long patients lived without the need for further drainage.
Estonian: Efektiivsuse põhinäitaja oli aeg, mille vältel patsiendid ei vajanud vedeliku uut eemaldamist.
English: The Committee for Medicinal Products for Human Use (CHMP) decided that Removab's benefits are greater than its risks for the intraperitoneal treatment of malignant ascites in patients with EpCAM-positive carcinoma where standard therapy is not available or no longer feasible.
Estonian: Inimravimite komitee otsustas, et Removabi kasulikkus on suurem kui kaasnevad riskid EpCAMpositiivset kartsinoomi põdevatel patsientidel esineva pahaloomulise astsiidi kõhukelmesiseses ravis juhtudel, kus standardravi ei saa kasutada või kui see ei ole enam teostatav.
English: Why has Removab been approved?
Estonian: Miks Removab heaks kiideti?
English: Removab treatment should only be given under the supervision of a doctor who has experience in the use of anticancer medicines.
Estonian: Ravi Removabiga peab toimuma üksnes vähiravimite kasutamises kogenud arsti järelevalve all.
English: These are cancers where the tumour cells have large quantities of a molecule called EpCAM on their surface.
Estonian: Need on vähkkasvajad, mille rakkude pinnal esineb suurel hulgal ainet EpCAM.
English: What is the risk associated with Removab?
Estonian: Mis riskid kaasnevad Removabiga?
English: What is Removab?
Estonian: Mis on Removab?
English: Removab should not be used in people who may be hypersensitive (allergic) to catumaxomab, to any of the other ingredients, or to murine (rat or mouse) proteins.
Estonian: Removabi ei tohi kasutada patsiendid, kes võivad olla katumaksomaabi, selle ravimi mis tahes muu koostisaine või hiirlaste (hiire või roti) valkude suhtes ülitundlikud (allergilised).
English: Catumaxomab has been designed to attach to two antigens: EpCAM, which is found in high levels on some types of cancer cells and CD3, which is found on T-cells.
Estonian: Katumaksomaab seondub kahe antigeeniga: EpCAMiga, mida esineb rohkesti teatavat tüüpi vähirakkude pinnal, ning CD3-ga, mis esineb T-rakkude pinnal.
English: Catumaxomab also attaches to a third substance called the Fc-gamma receptor, which also helps the body's immune system to target the cancer cells.
Estonian: Katumaksomaab seondub veel ka kolmanda molekuliga, Fcγ-retseptoriga, mis aitab samuti organismi immuunsüsteemil vähirakke hävitada.
English: Removab must be given as an intraperitoneal (into the peritoneal cavity) infusion using a pump system.
Estonian: Removabi tuleb manustada kõhukelmesisese (kõhuõõnde juhitava) infusioonilahusena, kasutades pumbasüsteemi.
English: On average, patients who received Removab lived for 46 days without the need for further drainage.
Estonian: Patsiendid, kellele manustati Removabi, elasid vedeliku uut eemaldamist vajamata keskmiselt 46 päeva ja patsiendid, keda raviti üksnes vedeliku eemaldamisega, 11 päeva.
English: The effects of Removab were first tested in experimental models before being studied in humans.
Estonian: Enne inimuuringuid kontrolliti Removabi toimet muude katsetega.
English: In patients with cancer, ascites forms because cancer cells develop on the peritoneum, the membrane around the peritoneal cavity, where they block the natural drainage of fluid from the abdomen.
Estonian: Vähipatsientide astsiit tekib, kui kõhuõõnt ümbritseval kõhukelmel arenevad vähirakud, mis blokeerivad vedeliku loomuliku äravoolu kõhuõõnest.
English: What benefit has Removab shown during the studies?
Estonian: Milles seisneb uuringute põhjal Removabi kasulikkus?
English: The full EPAR for Removab can be found here.
Estonian: Euroopa avaliku hindamisaruande täisteksti Removabi kohta leiate siit.
English: Removab with drainage was more effective at treating malignant acsites than drainage alone.
Estonian: Removab oli koos vedeliku eemaldamisega pahaloomulise astsiidi ravis efektiivsem kui üksnes vedeliku eemaldamine.
English: For the full list of all side effects reported with Removab, see the Package Leaflet.
Estonian: Removabi kohta teatatud kõrvalnähtude täieliku loetelu leiate pakendi infolehelt.
English: In this study, Removab used in combination with drainage of fluid from the abdomen was compared with drainage alone.
Estonian: Uuringus võrreldi Removabi toimet koos kõhuõõnest vedeliku eemaldamisega üksnes vedeliku eemaldamise toimega.
English: It contains the active substance catumaxomab.
Estonian: Ravim sisaldab toimeainena katumaksomaabi.
English: A monoclonal antibody is an antibody (a type of protein) that has been designed to recognise and attach to a specific structure
Estonian: Removabi toimeaine katumaksomaab on monoklonaalne antikeha (teatud valk), mis tunneb ära teatud antigeeni (organismi teatud rakkudel leiduva spetsiifilise struktuuri) ja seondub sellega.
English: How is Removab used?
Estonian: Kuidas Removabi kasutatakse?
English: By attaching to these two antigens, catumaxomab forms a bridge between the cancer cells and the T-cells.
Estonian: Katumaksomaab moodustab nende kahe antigeeniga seondudes silla vähirakkude ja T-rakkude vahele, tuues rakud üksteise lähedale, nii et T-rakud saavad vähirakke hävitada.
English: What is Removab used for?
Estonian: Milleks Removabi kasutatakse?
English: Removab is used to treat malignant ascites, fluid accumulation in the peritoneal cavity (abdominal space) that is caused by a cancer.
Estonian: Removabi kasutatakse pahaloomulise astsiidi ehk vähkkasvajast tingitud vedeliku kõhuõõnde kogunemise raviks.
English: Removab is a concentrate that is made up into a solution for infusion (a drip).
Estonian: Removab on kontsentraat, millest valmistatakse infusioonilahus.
English: How has Removab been studied?
Estonian: Kuidas Removabi uuriti?
English: How does Removab work?
Estonian: Kuidas Removab toimib?
English: 200 µg/ml
Estonian: 200 µg/ml Silmatilgad, lahus
English: Eye drops, solution Ocular use bottle (LDPE)
Estonian: Pudel (LDPE)
English: Pack size
Estonian: Okulaarne
English: IU/1200 IU solvent: 10 ml
Estonian: RÜ/2400 RÜ lahusti: 10 ml
English: Powder: 500
Estonian: Pakendi suurus pulber: 1000
English: MA(EU) number
Estonian: Müügiloa number Euroopa Liidus
English: The European Commission issued a decision on 2 June 2010.
Estonian: Euroopa Komisjon tegi otsuse 2. juunil 2010.
English: Prof. Pieter de Graeff (the Netherlands)
Estonian: prof Pieter de Graeff (Madalmaad)
English: Based on evaluation of the currently available data and the scientific discussion within the Committee, the CHMP concluded that the benefits of Clopidogrel Orion outweigh its risks and recommended that the marketing authorisation be granted in all the concerned Member States.
Estonian: Tuginedes olemasolevate andmete hindamisele ja komiteesisesele teaduslikule arutelule, jõudis inimravimite komitee järeldusele, et Clopidogrel Orioni kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda müügiloa kõigis asjaomastes liikmesriikides.
English: This is a procedure where one Member State (the ‘reference Member State', in this instance Germany) assesses a medicine with a view to granting a marketing authorisation that will be valid in this country as well as in other Member States (the ‘concerned Member States', in this instance the Czech Republic, Denmark, Finland, Lithuania, Latvia, Norway, Slovakia and Sweden).
Estonian: See on menetlus, mille käigus üks liikmesriik (viiteliikmesriik, praegusel juhul Saksamaa) hindab ravimit, et otsustada, kas anda ravimi müügiluba, mis kehtib selles riigis ja teistes liikmesriikides (asjaomased liikmesriigid, praegusel juhul Leedu, Läti, Norra, Rootsi, Slovakkia, Soome, Taani ja Tšehhi Vabariik).
English: What is Clopidogrel Orion?
Estonian: Mis on Clopidogrel Orion?
English: As the Member States were not able to reach an agreement, the German medicines regulatory agency referred the matter to the CHMP for arbitration on 29 October 2009.
Estonian: Liikmesriigid ei jõudnud küsimuses üksmeelele ja Saksamaa pädev asutus tegi 29. oktoobril 2009 inimravimite komiteele esildise vahekohtumenetluse alustamiseks.
English: Why was Clopidogrel Orion reviewed?
Estonian: Miks Clopidogrel Orioni taotlus uuesti läbi vaadati?
English: The European Medicines Agency has completed an arbitration procedure following a disagreement among Member States of the European Union (EU) regarding the authorisation of the medicine Clopidogrel Orion and associated names.
Estonian: Euroopa Ravimiamet (EMA) on lõpetanud vahekohtumenetluse, mis algatati pärast seda, kui Euroopa Liidu liikmesriigid ei jõudnud kokkuleppele ravimi Clopidogrel Orion ja sarnaste nimetuste heakskiitmises.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) has concluded that the benefits of Clopidogrel Orion outweigh its risks, and the marketing authorisation can be granted in Germany and in the following Member States of the EU: the Czech Republic, Denmark, Finland, Lithuania, Latvia, Norway, Slovakia and Sweden.
Estonian: EMA inimravimite komitee otsustas, et Clopidogrel Orioni kasulikkus on suurem kui sellega kaasnevad riskid ning ravimile võib anda müügiloa Saksamaal ning järgmistes Euroopa Liidu liikmesriikides: Leedu, Läti, Rootsi, Slovakkia, Soome, Taani ja Tšehhi Vabariik, samuti Norras.
English: The grounds for the referral were concerns from Sweden that patients would be exposed to the antioxidant butylated hydroxyanisole (BHA) unnecessarily.
Estonian: Esildise aluseks olid Rootsi kahtlused, et ravimist satub patsientide organismi tarbetult antioksüdanti butüülhüdroksüanisooli.
English: The company had chosen to use ‘clopidogrel base' as the form of the active substance in the medicine, and not a salt such as the ‘hydrogen sulfate salt' used in Plavix.
Estonian: Ettevõte valis ravimi toimeaine vormiks klopidogreelialuse ning mitte soola, nagu Plavixis kasutatav klopidogreelvesiniksulfaat.
English: It is used in adults to prevent atherothrombotic events (problems caused by blood clots and hardening of the arteries) such as a heart attack or stroke.
Estonian: Seda kasutatakse aterotrombootiliste nähtude (trombide ehk soonesiseste verehüüvete moodustumisest ja arterite lubjastumisest põhjustatud probleemide), näiteks infarkti või insuldi ennetamiseks täiskasvanutel.
English: 2 June 2010
Estonian: 2. juuni 2010
English: Teva Pharma B.V. submitted Clopidogrel Orion to Germany for a decentralised procedure.
Estonian: esitas Saksamaale taotluse Clopidogrel Orioni heakskiitmiseks detsentraliseeritud menetluse korras.
English: Clopidogrel Orion is a medicine that contains the active substance clopidogrel.
Estonian: Clopidogrel Orion on ravim, mille toimeaine on klopidogreel.
English: Clopidogrel Orion is a generic medicine based on a ‘reference medicine', Plavix, which is authorised in the EU.
Estonian: Clopidogrel Orion on geneeriline ravim, mille võrdlusravimil Plavixil on Euroopa Liidus juba müügiluba.
English: Clopidogrel base is less stable than the salt form, and BHA is included in the medicine to stabilise it..
Estonian: Klopidogreelialus ei ole sama stabiilne kui sool ning butüülhüdroksüanisooli lisatakse ravimile stabiliseerimise eesmärgil.
English: When the blood clots, this is due to special cells in the blood called platelets aggregating (sticking together).
Estonian: Veri hüübib teatud vererakkude - trombotsüütide (vereliistakute)agregatsiooni (kokkukleepumise) tõttu.
English: The active substance, clopidogrel, is an inhibitor of platelet aggregation.
Estonian: Ravimi toimeaine klopidogreel on trombotsüütide agregatsiooni inhibiitor, mis aitab ennetada organismis trombide tekkimist.
English: Date of first authorisation: 18 May 2018
Estonian: Müügiloa esmase väljastamise kuupäev: 18. mai 2018
English: If you are 65 or older, you have a greater risk.
Estonian: Kui olete 65-aastane või vanem, on teil risk suurem.
English: Other medicines and Zessly
Estonian: Muud ravimid ja Zessly
English: Radiographic changes were assessed in study 11.
Estonian: Radiograafilisi muutusi hinnati uuringus 11.
English: If you forget or miss your Zessly infusion
Estonian: Kui te unustate või jätate Zessly-infusiooni vahele
English: Zessly is indicated for:
Estonian: Zessly on näidustatud:
English: b greater values indicate more joint damage.
Estonian: b suuremad väärtused näitavad rohkem liigeskahjustusi.
English: Not known (frequency cannot be estimated from the available data)
Estonian: Teadmata: esinemissagedust ei saa hinnata olemasolevate andmete alusel
English: • You will be monitored while you are given Zessly and also for 1 to 2 hours afterwards.
Estonian: • Teid jälgitakse sel ajal, kui teile Zessly't manustatakse ja ka 1 kuni 2 tunni jooksul pärast seda.
English: All nails cleared c
Estonian: Kõik küüned puhtad c
English: Study 11*
Estonian: Uuring 11*
English: HAQ = Health Assessment Questionnaire; greater values indicate less disability.
Estonian: c HAQ = Tervise hindamise küsimustik (Health Assessment Questionnaire); suuremad väärtused näitavad väiksemat puuet.
English: EXP EXP, if not refrigerated
Estonian: EXP EXP säilitamisel väljaspool külmkappi
English: Your doctor will advise you what other medicines you must keep using while you are having Zessly.
Estonian: Teie arst annab teile nõu, milliste teiste ravimite kasutamist te peate jätkama Zessly saamise ajal.
English: Your doctor may recommend temporarily stopping Zessly.
Estonian: Teie arst võib soovitada Zessly ravi ajutiselt peatada.
English: Contents of the pack and other information What Zessly contains
Estonian: Pakendi sisu ja muu teave Mida Zessly sisaldab
English: What you need to know before you use Zessly You should not be given Zessly if:
Estonian: Mida on vaja teada enne Zessly kasutamist Teile ei tohi Zessly't manustada:
English: Patients with no deterioration/patients evaluated (%)c
Estonian: Patsiendid, kelle seisund pole halvenenud/ hinnatud patsiendid (%)c
English: • It is recommended that when Zessly is prepared for infusion, it is used as soon as possible (within 3 hours).
Estonian: • Kui Zessly on infusiooniks ette valmistatud, soovitatakse see manustada niipea kui võimalik (3 tunni jooksul).
English: b Absence of any draining fistulas.
Estonian: b eritist väljutavate fistulite puudumine.
English: What Zessly is and what it is used for
Estonian: Mis ravim on Zessly ja milleks seda kasutatakse
English: Zessly is also used in adults and children 6 years of age or older for:
Estonian: Zessly't kasutatakse ka täiskasvanutel ja 6-aastastel ja vanematel lastel:
English: Women of childbearing potential should consider the use of adequate contraception to prevent pregnancy and continue its use for at least 6 months after the last Zessly treatment.
Estonian: Rasestuda võivad naised peavad kaaluma adekvaatse rasestumisvastase vahendi kasutamist rasestumise vältimiseks ja jätkama selle kasutamist vähemalt 6 kuud pärast viimast Zessly-ravi.
English: Zessly belongs to a group of medicines called ‘TNF blockers'.
Estonian: Zessly kuulub ravimite gruppi, mida nimetatakse “TNF-i blokaatoriteks”.
English: Please read the Zessly ‘Package Leaflet' carefully before you start using this medicine.
Estonian: Lugege palun hoolikalt Zessly “Pakendi infolehte” enne kui te hakkate seda ravimit kasutama.
English: Zessly is not likely to affect your ability to drive or use tools or machines.
Estonian: Zessly ei mõjuta tõenäoliselt teie autojuhtimise või tööriistade või masinate käsitsemise võimet.
English: 2 weeks after your 1st treatment
Estonian: 2 nädalat pärast teie 1. annust
English: • You are allergic to infliximab or to any of the other ingredients of this medicine (listed in section 6).
Estonian: • kui te olete infliksimabi või selle ravimi mis tahes koostisosade (loetletud lõigus 6) suhtes allergiline;
English: PREGNANCY AND VACCINATIONS
Estonian: RASEDUS JA VAKTSINEERIMINE
English: Study 4 (week-2 responders) % of Patients
Estonian: Uuring 4 (nädal 2 ravivastuse saavutanud) Patsientide %
English: If you forget or miss an appointment to receive Zessly, make another appointment as soon as possible.
Estonian: Kui te unustate või jätate vahele kokkulepitud Zessly manustamise, pange endale niipea kui võimalik kirja uus aeg.
English: N ≥ 90% improvement
Estonian: N ≥ 90% paranemine
English: If you are given too much Zessly
Estonian: Kui teile manustatakse liiga palju Zessly't
English: Median follow-up is based on patients treated.
Estonian: 4 Jälgimisperioodi mediaan põhineb ravitud patsientidel.
English: • Circulation problems such as low or high blood pressure,
Estonian: • vereringeprobleemid, nagu madal või kõrge vererõhk;
English: Between weeks 6 and 26, symptoms of psoriasis gradually returned with a median time to disease relapse of > 20 weeks.
Estonian: 6. ja 26. nädala vahelisel perioodil psoriaasi sümptomid järk-järgult taastusid ning keskmine haiguse taastekke aeg oli > 20 nädalat.
English: Therefore, the combination of Zessly and anakinra is not recommended.
Estonian: Seetõttu ei ole Zessly ja anakinra kombineerimine soovitatav.
English: The requirements for submission of PSUR for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.
Estonian: Nõuded asjaomase ravimi perioodiliste ohutusaruannete esitamiseks on sätestatud direktiivi 2001/83/EÜ artikli 107c punkti 7 kohaselt liidu kontrollpäevade loetelus (EURD loetelu) ja iga hilisem uuendus avaldatakse Euroopa ravimite veebiportaalis.
English: INFECTIONS Before treatment with Zessly
Estonian: INFEKTSIOONID Enne ravi Zessly'ga